IQVIA Holdings Inc. (IQV) Stock Price & Analysis
IQVIA Holdings Inc. (IQV) — MoonshotScore 71/100 (Strong band), calculated Nov 22, 2026. Price $245.82 (-1.89%), as of the Nov 20, 2026 trading session; market cap $40.5B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
IQVIA Holdings Inc. · IQV · NYSE · Healthcare · Medical Diagnostics & Research
Research dated 2026-09-12: IQVIA sells clinical-trial execution, laboratory support, healthcare data, analytics software, consulting, and outsourced commercial services to life-sciences companies; it is not primarily a diagnostics manufacturer despite its industry classification. Revenue is expanding, but the defining question is whether that growth can produce enough earnings and cash to comfortably carry a debt-heavy capital structure.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · IQVIA Holdings (IQV)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 5 of the last 8 reports
- expected results Feb 4, 2027
- Altman Z 2.18 · Piotroski F 8
Holding back: balance-sheet strain
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 72 | Strong | |
| 71 | Strong | |
| 71 | Strong | |
| 71 | Strong | |
| 71 | Strong | |
| 71 | Strong |
The score was 71 in the stored Nov 21, 2026 snapshot and remains 71 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Valuation -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $245.82 | |
| Change on the day | -1.89% | |
| 52-week range | $154.50–$284.50 | |
| Market capitalisation | $40.5B | — |
| Price / earnings (trailing) | 29.55 | |
| Shares traded on the day | 1.25M | |
| Beta (volatility vs the S&P 500) | 1.16 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for IQVIA Holdings (IQV): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Klarman-style lens and Financial health lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is IQVIA Holdings (IQV), and what does it report?
Short answer · as of
Research and Development Solutions manages clinical trials, monitoring, virtual-trial support, study design, and laboratory services.
Research dated 2026-09-12.
Technology and Analytics Solutions supplies healthcare data, cloud applications, implementation, analytics, consulting, and commercial-process outsourcing, while Contract Sales and Medical Solutions handles engagement and medical-affairs work.
Reported revenue therefore combines project-based research activity with technology, data, consulting, and outsourced commercialization. Research and Development Solutions is the largest contributor, Technology and Analytics Solutions is also substantial, and Contract Sales and Medical Solutions is considerably smaller.
What do the latest results show for IQVIA Holdings (IQV)?
Research dated 2026-09-12.
Revenue reached the highest level in the displayed quarterly series, and gross profit increased from the preceding period. Operating profit and net income nevertheless declined sequentially as selling, general, and administrative expense rose, so the latest growth did not produce matching earnings expansion.
The same tension appears in the annual record: revenue advanced while net income slipped slightly in the latest completed year. Against market expectations, however, reported revenue and earnings exceeded estimates throughout the displayed earnings history.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $4.10B | $331M | $1.93 (diluted) |
| Q4 FY2025 | $4.36B | $514M | $2.99 (diluted) |
| Q1 FY2026 | $4.15B | $274M | $1.61 (diluted) |
| Q2 FY2026 | $4.37B | $256M | $1.53 (diluted) |
What are the financial strengths and risks for IQVIA Holdings (IQV)?
Short answer · as of
The MoonshotScore pillars rate business quality, durable growth, positive momentum as strengths.
Research dated 2026-09-12.
Operating cash flow remained positive throughout the displayed quarterly series, and cash plus short-term investments ended above the level shown at the beginning of that history. Cash generation fluctuates meaningfully between periods, making consistency as important as the headline amount.
Debt stands far above cash and investments, while the current and quick ratios indicate that current assets do not fully cover current liabilities. That leverage leaves IQVIA more exposed if trial activity, technology demand, or commercial outsourcing weakens while operating costs remain elevated; the valuation also provides limited tolerance for an earnings shortfall.
What should you watch next at IQVIA Holdings (IQV)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
Research dated 2026-09-12.
The next earnings release should be judged on conversion rather than revenue alone. Consensus expects revenue near the latest run rate and earnings above the latest reported figure, so operating profit, net income, and selling, general, and administrative expense will show whether growth is becoming more productive.
Research and Development Solutions deserves particular attention because it contributes the most segment revenue. Beyond the approaching report, analyst averages assume continued revenue and earnings expansion, making sustained cash generation and balance-sheet progress important checks on that trajectory.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does IQVIA Holdings compare with its peers?
Short answer
IQVIA Holdings's score ranks 6th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
IQVIA combines clinical-research execution with healthcare data, analytics technology, consulting, laboratories, and outsourced commercial engagement. A narrower contract-research business is more directly tied to trial activity, while a healthcare-data or software vendor leans more heavily on application adoption, implementation, and analytical demand; IQVIA carries these exposures together.
That breadth can spread demand across the drug-development and commercialization cycle, but it also makes consolidated profitability sensitive to which services are growing. The large research operation and substantial technology-and-analytics business mean segment mix matters alongside total revenue.
| Company | Price | Market value | Score |
|---|---|---|---|
| $235.63 Nov 20, 2026 | $33.1B | 95 5-pillar Nov 22, 2026 | |
| $272.81 Nov 20, 2026 | $63.1B | 89 5-pillar Nov 22, 2026 | |
| $170.38 Nov 20, 2026 | $48.0B | 84 5-pillar Nov 22, 2026 | |
| $74.31 Nov 20, 2026 | $35.7B | 81 5-pillar Nov 22, 2026 | |
| $9.07 Nov 20, 2026 | $39.8B | 76 5-pillar Nov 22, 2026 | |
| IQVIA Holdings (IQV) — this page | $245.82 | $40.5B | 71 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $240.00 – $346.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $291.33
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $300.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 9, 2026
- Transactions
- 28
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 10
- Other transactions
- 18
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IQV in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.21% | $47.77M | Added +577.9% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about IQVIA Holdings (IQV)?
Common Questions About IQV (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does IQVIA make money from clinical trials and healthcare data?
IQVIA earns revenue by managing and supporting clinical studies, operating laboratory services, supplying healthcare data and analytics applications, implementing technology, advising clients, and outsourcing commercial and medical work. Demand comes from pharmaceutical, biotechnology, medical-device, diagnostic, and consumer-health companies.
Which IQVIA segment contributes the most revenue?
Research and Development Solutions is the largest revenue contributor, ahead of Technology and Analytics Solutions. Contract Sales and Medical Solutions is much smaller than either core operation.
Has IQVIA’s recent revenue growth produced higher profit?
Not consistently. The latest quarter delivered stronger revenue and gross profit, but operating profit and net income fell from the preceding period, while the latest annual revenue increase coincided with a slight decline in net income.
How exposed is IQVIA to debt despite its cash generation?
Debt substantially exceeds cash and investments, and short-term liquidity ratios remain below parity. Positive operating cash flow helps service that burden, but weaker demand or sustained cost pressure would reduce the available cushion.
What is the IQV stock price today?
The last price recorded for IQVIA Holdings Inc. (IQV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IQV price target?
The last analyst consensus price target we captured for IQVIA Holdings Inc. (IQV), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 1 from SEC filings and earnings calls, 13 from Financial Modeling Prep (FMP), 4 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold IQV
Funds in our ETF coverage that list IQV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 5.67% |